Clinical Edge

Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions

One-third of IDH1-mutated AML cases have complete response to ivosidenib

Pollyea DA, et al. J Clin Oncol 36, 2018 (suppl) annual meeting of the American Society of Clinical Oncology; abstr 7000.

Key clinical point: Daily oral ivosidenib was associated with a complete response rate of nearly 32% and a low rate of serious adverse events in patients with IDH1-mutated relapsed/refractory acute myeloid leukemia (AML).

Major finding: Patients with complete responses had an 8.2-month duration of response, and a median overall survival of 18.8 months.

Study details: A phase 1 study including 179 patients who received 500 mg of ivosidenib daily.

Disclosures: Daniel A. Pollyea, MD, who presented the study, reported disclosures related to Abbvie, Agios, argenx, Celgene, Celyad, Curis, Pfizer, and Servier.

Source: Pollyea DA, et al. J Clin Oncol 36, 2018 (suppl) annual meeting of the American Society of Clinical Oncology; abstr 7000.

Read the article.

Citation:

Pollyea DA, et al. J Clin Oncol 36, 2018 (suppl) annual meeting of the American Society of Clinical Oncology; abstr 7000.

This Week's Must Reads

Policy statement on access to opioid medications, Statement on Opioid Use in Patients with Hematologic Diseases and Disorders, American Society of Hematology

FDA approves Mircera for dialysis-related anemia in pediatric patients, FDA approved-drug notice, June 7, 2018; Mircena label (Drugs@FDA)

FDA approves pembrolizumab for relapsed/refractory PMBCL, FDA Press Announcement, June 15, 2018; Keytruda Prescribing Information (Drugs@FDA)

Poor adherence to DOAC therapy requires attention, Lakkireddy D et al. Heart Rhythm 2018, Abstract B-LBCT02-03.

Red cell tranfusion may increase risk of postsurgical VTE, Goel R et al. JAMA Surg. 2018 Jun 13. doi: 10.1001/jamasurg.2018.1565

Must Reads in AML

One-third of IDH1-mutated AML cases have complete response to ivosidenib , Pollyea DA, et al. J Clin Oncol 36, 2018 (suppl) annual meeting of the American Society of Clinical Oncology; abstr 7000.

New option for IDH1-mutated AML, Pollyea DA, et al. J Clin Oncol 36, 2018 (suppl; abstr 7000).

Adding statin boosted AML response rate, Advani AS et al. Leuk Res. 2018 Apr;67:17-20.

Pembrolizumab after cytarabine boosts AML response, Zeidner J et al. Acute Leukemia Forum 2018, Poster Session.

Over half of refractory AML patients responded to combo, Advani A et al. ASH 2017, Abstract 150.